BIAF on Nasdaq
bioAffinity Technologies, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with VITASPRING BIOMEDICAL CO. LTD., Absci Corp or FOXO TECHNOLOGIES INC., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-171.6%Operating margin3
-242.0%Net margin3
-34.2%Revenue growth, 20253
-204.9%Return on equity3
-$9.4MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Health Care, Patient Service brought in 81% of the revenue bioAffinity Technologies, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Health Care, Patient Service | $8.2M | $5.0M |
| Histology Service Fees | $1.1M | $1.1M |
| Medical Director Fees | $66.6K | $68.3K |
| Other Revenues | $7.4K | $4.9K |
| Department of Defense Observational Studies | $8.7K | $577 |
| Diagnostic Research And Development | $8.7K | $577 |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development12¢$1.4M
- Selling, general and admin87¢$9.9M
- Income tax0¢$44.0K
Out of $6.2M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Revenue | $6.2M | $9.4M |
| Direct costs and expenses | $4.2M | $6.0M |
| Research and development | $1.4M | $1.5M |
| Clinical development | $705.7K | $321.7K |
| Selling, general and administrative | $9.9M | $9.9M |
| Depreciation and amortization | $504.8K | $605.6K |
| Total operating expenses | $16.7M | $18.3M |
| Loss from operations | -$10.6M | -$9.0M |
| Interest income | $23.4K | $17.6K |
| Interest expense | -$44.4K | -$92.5K |
| Other income | $40.5K | $10.3K |
| Other expense | -$502.4K | -$10.2K |
| Change in fair value of warrants issued | -$3.8M | |
| Loss before income tax expense | -$14.9M | -$9.0M |
| Income tax expense | -$44.0K | -$11.7K |
| Net loss | -$14.9M | -$9.0M |
| Net loss per common share, basic | -$8.66 | -$22.50 |
| Net loss per common share, diluted | -$8.66 | -$22.50 |
| Weighted average common shares outstanding, basic | 1.7M shares | 404.2K shares |
| Weighted average common shares outstanding, diluted | 1.7M shares | 404.2K shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2025-07-31 | 2025-05-31 |
|---|---|---|---|
| Cash and cash equivalents | $6.4M | ||
| Accounts and other receivables, net | $542.0K | ||
| Inventory | $53.5K | ||
| Prepaid expenses and other current assets | $519.9K | ||
| Total current assets | $7.6M | ||
| Property and equipment, net | $265.6K | ||
| Operating lease right-of-use asset, net | $334.3K | ||
| Finance lease right-of-use asset, net | $661.6K | ||
| Goodwill | $1.4M | ||
| Intangible assets, net | $716.8K | ||
| Other assets | $12.8K | ||
| Total assets | $11.0M | ||
| Accounts payable | $761.9K | ||
| Accrued expenses | $1.7M | ||
| Unearned revenue | $42.4K | ||
| Operating lease liability, current portion | $139.2K | ||
| Finance lease liability, current portion | $139.5K | ||
| Notes payable, current portion | $105.2K | ||
| Total current liabilities | $2.9M | ||
| Operating lease liability, net of current portion | $202.9K | ||
| Finance lease liability, net of current portion | $532.8K | ||
| Notes payable, net of current portion | $41.3K | ||
| Total liabilities | $3.7M | ||
| Preferred stock, $0.001 per share; 20,000,000 shares authorized; 700 and 0 shares issued and outstanding at December 31, 2025 and 2024, respectively | $1 | ||
| Common Stock, par value $0.007 per share; 350,000,000 shares authorized; 4,498,675 and 519,158 issued and outstanding at December 31, 2025 and 2024, respectively() | $31.5K | $5.8M | |
| Additional paid-in capital(1) | $75.8M | ||
| Accumulated deficit | -$68.6M | ||
| Total stockholders equity | $7.3M | ||
| Total liabilities and stockholders equity | $11.0M | ||
| Preferred stock, par value | $0.00 | ||
| Preferred stock, shares authorized | 20.0M shares | ||
| Preferred stock, shares issued | 700 shares | ||
| Preferred stock, shares outstanding | 700 shares | ||
| Common Stock, Par or Stated Value Per Share | $0.01 | ||
| Common Stock, Shares Authorized | 350.0M shares | 350.0M shares | |
| Common Stock, Shares, Issued | 4.5M shares | ||
| Common Stock, Shares, Outstanding | 4.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$14.9M | -$9.0M |
| Depreciation and amortization | $504.8K | $605.6K |
| Stock-based compensation expense | $671.5K | $989.7K |
| Fair value adjustment on warrants | $3.8M | |
| Accounts and other receivables | $597.2K | -$327.5K |
| Inventory | -$25.9K | -$9.1K |
| Prepaid expenses and other assets | -$90.1K | -$105.6K |
| Accounts payable | -$225.4K | $382.5K |
| Accrued expenses | $319.3K | $248.9K |
| Unearned revenue | $18.0K | -$8.7K |
| Operating lease right-of-use asset | $1.2K | -$812 |
| Net cash used in operating activities | -$9.3M | -$7.3M |
| Purchase of property and equipment | -$60.6K | -$79.1K |
| Net cash used in investing activities | -$60.6K | -$79.1K |
| Proceeds from issuance of Common Stock from direct offering | $11.1M | $5.6M |
| Proceeds from exercised stock options | $74.9K | |
| Proceeds from exercise of warrants | $4.8M | $1.4M |
| Proceeds from issuance of Convertible Preferred Stock | $990.0K | |
| Payment of offering costs for financing activities | -$1.8M | -$1.3M |
| (Payments) proceeds from loans payable | -$45.4K | $191.8K |
| Principal repayments on finance leases | -$324.3K | -$361.2K |
| Net cash provided by financing activities | $14.7M | $5.6M |
| Net change in cash and cash equivalents | $5.3M | -$1.7M |
| Income taxes paid in cash | $44.0K | $11.7K |
| Interest paid | $23.4K | $17.6K |
| Fair value of warrants issued to placement agents | $74.3K |
Recent filings
- Oct 13, 2026PRER14A
- Oct 13, 20268-K
- Oct 9, 2026424B5
- Oct 9, 2026424B5
- Oct 9, 20268-K
- Oct 8, 20268-K
- Oct 6, 20268-K
- Sep 30, 20268-K
- Sep 29, 2026PRE 14A
- Sep 22, 20268-K
- Sep 17, 20268-K
- Sep 11, 20268-K
- Sep 9, 20268-K
- Sep 8, 2026424B3
- Sep 4, 2026EFFECT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8